Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer

• Hauptverfasser: Zehui Tan (Verfasst von), Ning Guo (Verfasst von), Zhi Cao (Verfasst von), Shuyu Liu (Verfasst von), Jiayu Zhang (Verfasst von), Deyi Ma (Verfasst von), Jiahao Zhang (Verfasst von), Wencai Lv (Verfasst von), Nan Jiang (Verfasst von), Linghe Zang (Verfasst von), Lihui Wang (Verfasst von), Xin Zhai (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2024-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Recent research certified that DOT1L and its mutations represented by R231Q were potential targets for the treatment of lung cancer. Herein, a series of adenosine-containing derivatives were identified with DOT1LR231Q inhibition through antiproliferation assay and Western blot analysis in the H460R2...